A Novel Approach to ALS Trial Development
1:00:31
Review insights on ALS studies and recruitment challenges involving newly diagnosed rare disease participants.
The Template for a Successful Digital Trial
1:00:43
Industry Leaders Marie Mc Carthy (ICON PLC) and Chen Admati (Intel) explore a few best practices for implementing a successful digital trial
Industry Perceptions and Expectations_ The Role of ICER as an Independent HTA
1:02:20
This webinar explores: the evolution of health technology assessment in the US and possibilities for the future; opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system; ICER methodologies and approaches
Industry Analysis_ Impact of FDA’s Recent Guidance on Payer Communications
57:23
Our experts explore how manufacturers can successfully implement the FDA's guidance on Payer Communications and integrate these new communication channels with payers
NASH Clinical Trials: Challenges and Considerations
46:50
Dr. Andrew Roche discusses overcoming the challenges and considerations associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
How Real World Evidence Continues to Shape the Late Phase Research Landscape
58:20
This webinar explores Real World Evidence Dynamics and Alignment with Late Phase Research, Developing an RWE Strategy and Connecting Technology to an RWE Strategy. Presented by Bill Row, Holly Watts, Bruce Capobianco
eConsent - Better for the Patient, Better for the Site
1:03:18
This webinar explores the latest industry and regulatory developments relating to the use of eConsent in clinical trials and what sponsors and sites need to consider before they deploy this in clinical trials.
A Novel Approach to ALS Trial Development
Review insights on ALS studies and recruitment challenges involving newly diagnosed rare disease participants.
1:00:31
The Template for a Successful Digital Trial
Industry Leaders Marie Mc Carthy (ICON PLC) and Chen Admati (Intel) explore a few best practices for implementing a successful digital trial
1:00:43
Industry Perceptions and Expectations_ The Role of ICER as an Independent HTA
This webinar explores: the evolution of health technology assessment in the US and possibilities for the future; opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system; ICER methodologies and approaches
1:02:20
Industry Analysis_ Impact of FDA’s Recent Guidance on Payer Communications
Our experts explore how manufacturers can successfully implement the FDA's guidance on Payer Communications and integrate these new communication channels with payers
57:23
NASH Clinical Trials: Challenges and Considerations
Dr. Andrew Roche discusses overcoming the challenges and considerations associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
46:50
How Real World Evidence Continues to Shape the Late Phase Research Landscape
This webinar explores Real World Evidence Dynamics and Alignment with Late Phase Research, Developing an RWE Strategy and Connecting Technology to an RWE Strategy. Presented by Bill Row, Holly Watts, Bruce Capobianco
58:20
eConsent - Better for the Patient, Better for the Site
This webinar explores the latest industry and regulatory developments relating to the use of eConsent in clinical trials and what sponsors and sites need to consider before they deploy this in clinical trials.
1:03:18
Clinical Research Services Webinars
-
The Template for a Successful Digital Trial
Industry Leaders Marie Mc Carthy (ICON PLC) and Chen Admati (Intel) explore a few best practices for implementing a successful digital trial
1:00:43
-
Risk Based Monitoring: The Site Perspective
PCT Digital Week webinar. Risk based monitoring has been emerging for years. The 2017 release of ICH E6 R2 introduced the world of technology to a 20-year-old guideline with increased focus on delivering quality and efficiencies in clinical trials. T
56:34
-
What is next in eCOA
In this webinar, we review the accumulating evidence to support measurement equivalence of instruments when migrated to ePRO. We review meta analyses of published quantitative equivalence studies, and a newly published meta synthesis of unpublished c
48:36
-
eConsent - Better for the Patient, Better for the Site
This webinar explores the latest industry and regulatory developments relating to the use of eConsent in clinical trials and what sponsors and sites need to consider before they deploy this in clinical trials.
1:03:18
-
Bring your own device
This webinar discusses how we can develop a methodology and minimum standards for migrating instruments that would be applicable to any device.
1:04:04
-
Bring your own device (BYOD) eCOA – Instrument Validation Methodology
This webinar discusses how we can develop a methodology and minimum standards for migrating instruments that would be applicable to any device.
1:02:33
-
Activity Monitoring: Wearables_Setting the Standards for Clinical Research
This webinar will focus on free-living activity in clinical trials including wearables/sensors and accelerometers
44:36
-
Leveraging Smart Phone Sensors to Measure Novel Health Outcomes
This webinar examines the use of the increasingly ubiquitous smartphone as a platform to measure a variety of novel health-related endpoints that may have value in clinical trials.
1:01:10
Commercialisation & Outcomes Webinars
-
Overcoming 5 Common Barriers to Harmonised Real World Data
53:28
-
Effective Ingestion and Normalisation of Real World Data Sources
50:02
-
Engagement and Retention of Patients in Clinical Trials
44:46
-
Applying the Latest Digital Technology Trends to Patient, Provider and Payer Communications
This webinar reviews current trends and how digital technology and innovation are being applied to patient, healthcare professional, payer, and other decision maker communications.
51:01
-
Industry Perceptions and Expectations_ The Role of ICER as an Independent HTA
This webinar explores: the evolution of health technology assessment in the US and possibilities for the future; opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system; ICER methodologies and approaches
1:02:20
-
What is next in eCOA
In this webinar, we review the accumulating evidence to support measurement equivalence of instruments when migrated to ePRO. We review meta analyses of published quantitative equivalence studies, and a newly published meta synthesis of unpublished c
48:36
-
Industry Analysis_ Impact of FDA’s Recent Guidance on Payer Communications
Our experts explore how manufacturers can successfully implement the FDA's guidance on Payer Communications and integrate these new communication channels with payers
57:23
-
Bring your own device (BYOD) eCOA – Instrument Validation Methodology
This webinar discusses how we can develop a methodology and minimum standards for migrating instruments that would be applicable to any device.
1:02:33
-
Market Access Hurdles for Cell and Gene Therapies: Managing Evidence to Enhance Market Adoption
The emergence and rise of gene and cell therapies has the potential to significantly change the way we manage and treat disease. While payers recognize that gene and cell therapies are likely to be the next big step in the evolution of medicine, the
31:44
-
Evolving Best Practices for Working with Authors – Authorship and Beyond
Our experts discuss examine good publication practices that will help to streamline your interactions with scientific authors, while enhancing the quality, efficiency and effectiveness of your industry sponsored research projects.
31:32
-
Outcomes-Based Agreements and Innovative Contracting for Biopharmaceutical
Learn why traditional contracting may not be enough to address the needs of both payers and pharma manufacturers
58:48
-
Optimise your Regulatory & HTA Submissions with a Comprehensive Health Economic & Epidemiologic Evidence Strategy
Learn how having a comprehensive health economic and epidemiologic evidence strategy and evidence generation plan can optimise your regulatory and HTA submissions.
52:00
